menu
    • menu

    Company profile for Larifans Ltd

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    An original pharmaceutical product - Larifan (Lariphan) is developed at the Latvian Academy of Sciences and at present is produced at Larifāns Ltd (Larifan Ltd). Larifan is a double-stranded RNA (dsRNA) of natural origin obtained from bacteriophage-infected E.coli cells. It is a heterogeneous population of dsRNA molecules with the mean molecular mass of about 500 kDa and the average length of RNA is 400 nt/p. Larifan (dsRNA) ...
    An original pharmaceutical product - Larifan (Lariphan) is developed at the Latvian Academy of Sciences and at present is produced at Larifāns Ltd (Larifan Ltd). Larifan is a double-stranded RNA (dsRNA) of natural origin obtained from bacteriophage-infected E.coli cells. It is a heterogeneous population of dsRNA molecules with the mean molecular mass of about 500 kDa and the average length of RNA is 400 nt/p. Larifan (dsRNA) has been developed as a new poly-functional and wide-spectrum medical drug for viral and oncological diseases. Larifan possesses various biological activities like interferon - inducing, immunomodulating, antiviral, antitumoral and antimutagenic properties. These activities are a result of the action of the induced endogenous interferon, but they also may be provoked directly by the dsRNA molecule. Some drug forms such as ointment and injection form are being produced for human use; clinical trial of suppositories is in progress. The injection drug form is registered in the Drug Register of Latvia. Some cosmetic Larifan-containing products – antiviral lip balm, tooth paste, spray and medical device forms – suppositories and pesaries are being produced as well. Larifan clinical efficacy has been studied in different clinics and institutes of Latvia and previous USSR since the 80-ties of the last century.In human clinics Larifan is employed as an immunomodulator with antiviral and antitumoral activities. Its therapeutic antiviral effect has been demonstrated in the treatment of herpes (in Russian, Ukrainian, Latvian clinics), papilloma, respiratory a.o. virus infections. Larifan advantage when compared with chemical antiviral preparations is its broad antiviral spectrum and absence of immunosuppressive properties. Because of its interferoninducing ability Larifan exposes a theoretically universal antiviral spectrum. Immunomodulating activities are responsible for correction of the immunodeficiency characteristic for many viral infections. When compared with exogenous interferons Larifan - induced endogenous interferon should be considered as a more physiologic one and thus having less side effects. The endogenous interferon is supposed to be more stable, with more prolonged action and better distribution in the organism. Regarding antitumoral potential there is evidence enough to consider Larifan a perspective drug for malignant diseases. Its ability to possess both antitumoral and immunomodulating properties at the same time is of special value for oncology. In oncology Larifan may be applied in combined biotherapy schedules aimed to change surface antigens of malignant cells and activate immunocompetent effector cells as well. Results of scientific investigations are published in articles and abstracts.The method of manufacturing of dsRNA is patented in Latvia.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Larifans LtdLatvia Flag
    Country
    Country
    Latvia
    Address
    Address
    Kurbada str. 2b Riga, Latvia LV-1009
    Telephone
    Telephone
    +371 67427462
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.larifans.lv/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search